Helgi van de Velde
AVEO Oncology (United States)(US)Sanofi (United States)(US)Sanofi (Belgium)(BE)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma(2008)1,900 cited
- → Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.(2011)1,622 cited
- → Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma(2016)1,044 cited
- → Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study(2011)912 cited
- → Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer(2004)773 cited
- → Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial(2010)